Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...

In this video, Francesca Jackson-Spence,MBChB, BSc, shares data from the study, “Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO; NCT02819596),” ...

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

A Waukesha County deputy is battling a "rare, aggressive cancer." Steve Lyles has been with the department for nearly 20 ...

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.

A Waukesha County sheriff’s deputy, Steve Lyles, fights a rare cancer with a positive attitude and dedication to his job. His ...

Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...

The most common reason for cisplatin-ineligibility is renal function impairment. Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min ...